Autolus Therapeutics plc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.03
Dividend & YieldN/A$ (N/A)
Beta 1.53
Market capitalization 228.74M
Operating cash flow -106.9M
ESG Scores unknown

Company description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.3M -1.45M 1.44M -1.82M
Total Cashflows From Investing Activities -13.19M -18.67M -14.68M -8.86M
Net Borrowings
Total Cash From Financing Activities 156.49M 108.86M 74.42M 284.06M
Change To Operating Activities 2.36M -14.75M -29k 5.95M
Issuance Of Stock 159.66M 115.96M 80.21M 246.03M
Net Income -57.88M -123.85M -142.09M -142.1M
Change In Cash 88.57M -6.12M -57.34M 156.59M
Effect Of Exchange Rate -12.2M 5.16M 679k -754k
Total Cash From Operating Activities -42.52M -101.48M -117.76M -117.86M
Depreciation 1.99M 4.56M 5.57M 8.37M
Change To Account Receivables
Other Cashflows From Financing Activities -7.1M -7.1M -5.8M 38.04M
Change To Netincome 9.7M 33.96M 17.27M 11.64M
Capital Expenditures -12.78M -18.34M -14.68M -8.86M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -66.36M -139.01M -166.26M -165.99M
Net Income -57.88M -123.85M -142.09M -142.1M
Selling General Administrative 25.6M 39.45M 34.97M 31.86M
Gross Profit -46.83M -102.51M -133.17M -132.46M
Ebit -72.43M -141.96M -168.15M -164.32M
Operating Income -72.43M -141.96M -168.15M -164.32M
Interest Expense -1.1M -1.1M -1.1M -1.1M
Income Tax Expense -8.49M -15.16M -24.16M -23.89M
Total Revenue 1.47M 2.91M 1.72M 2.33M
Cost Of Revenue 48.3M 105.42M 134.89M 134.79M
Total Other Income ExpenseNet 6.06M 2.95M 1.89M -1.66M
Net Income From Continuing Ops -57.88M -123.85M -142.09M -142.1M
Net Income Applicable To Common Shares -57.88M -123.85M -142.09M -142.1M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 21.57M 48.69M 84.2M 92.24M
Total Stockholder Equity 232.64M 254.84M 210.03M 313.32M
Other Current Liabilities 2.27M 1.77M 701k 160k
Total Assets 254.21M 303.53M 294.24M 405.56M
Common Stock 2k 2k 3k 4k
Other Current Assets 105k 1.07M 3.79M 1.65M
Retained Earnings -113.3M -237.15M -379.24M -521.34M
Treasury Stock -15.37M -8.57M -5.74M -8.45M
Cash 217.45M 210.64M 153.3M 310.34M
Total Current Liabilities 21.08M 24.98M 33.63M 28.55M
Other Stockholder Equity -15.37M -8.57M -5.74M -8.45M
Property, Plant, and Equipment 19.97M 51.57M 89.68M 52.32M
Total Current Assets 232.97M 249.26M 196.98M 346.95M
Net Tangible Assets 232.64M 254.59M 209.87M 313.25M
Net Receivables 13.34M 30.52M 29.68M 26.25M
Accounts Payable 2.02M 1.07M 2.26M 431k


Insider Transactions

Here are the insider transactions of stock shares related to Autolus Therapeutics plc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Autolus Therapeutics plc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Autolus Therapeutics plc

Here is the result of two systematic investment strategies applied to Autolus Therapeutics plc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Autolus Therapeutics plc

The following chart shows the equity curve of the two systematic investment strategies applied to Autolus Therapeutics plc:

Autolus Therapeutics plc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -43.19% on the backtest period.

Performance at glance

Performance

-43.19 %

Latent gain

-748.05 $

Invested capital

1732.17 $

Annualized return

-12.27 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Autolus Therapeutics plc

This is the result of two momentum investment strategies applied to Autolus Therapeutics plc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Autolus Therapeutics plc

The following chart shows all the entries opened by the momentum investment system on Autolus Therapeutics plc:

Autolus Therapeutics plc momentum entries
  • The first momentum investment strategy would give -53.15% of return on Autolus Therapeutics plc. That represents -1999.51$ of latent gain with 3762.03$ of employed capital.
  • The second momentum investment strategy would give -38.93% of return on Autolus Therapeutics plc. That represents -1077.5$ of latent gain with 2767.74$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-53.15 %

Latent gain

-1999.51 $

Invested capital

3762.03 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-38.93 %

Latent gain

-1077.5 $

Invested capital

2767.74 $

Annualized return

-12.81 %

Momentum equity curve on Autolus Therapeutics plc

The following chart shows the equity curve of the two momentum strategies applied to Autolus Therapeutics plc:

Autolus Therapeutics plc momentum equity

Note: the dividends potentially given by Autolus Therapeutics plc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Autolus Therapeutics plc

The following chart shows the employed capital evolution of the two momentum strategies on Autolus Therapeutics plc since the beginning:

Autolus Therapeutics plc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Autolus Therapeutics plc

Buy the dip entry openings on Autolus Therapeutics plc

Autolus Therapeutics plc

The performance achieved by the robo-advisor on Autolus Therapeutics plc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Autolus Therapeutics plc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Autolus Therapeutics plc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Autolus Therapeutics plc

The following chart shows the result of the investment strategy applied to Autolus Therapeutics plc:

Autolus Therapeutics plc

Note: the dividends potentially given by Autolus Therapeutics plc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Autolus Therapeutics plc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Autolus Therapeutics plc:

Autolus Therapeutics plc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Autolus Therapeutics plc

In this section, I will compare the three previous investment strategies applied to Autolus Therapeutics plc.

Equity curve comparison on Autolus Therapeutics plc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Autolus Therapeutics plc investment strategy comparison

Employed capital comparison on Autolus Therapeutics plc

Autolus Therapeutics plc investment comparison

Performance comparison on Autolus Therapeutics plc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -43.19% -748.05$ 1732.17$ -12.27%
Momentum 1 quarter -53.15% -1999.51$ 3762.03$ -16.2%
Momentum 2 quarters -38.93% -1077.5$ 2767.74$ -12.81%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-12.27 %

Momentum 1Q

-12.81 %

Momentum 2Q

-12.81 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Autolus Therapeutics plc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • NOVACYT

  • Note: The algorithm computes the probability of correlation between Autolus Therapeutics plc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Autolus Therapeutics plc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Autolus Therapeutics plc
    Country United Kingdom
    City London
    Address The MediaWorks
    Phone 44 20 3829 6230
    Website www.autolus.com
    FullTime employees 324
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker AUTL
    Market www.nasdaq.com

    Autolus Therapeutics plc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown